Drugs in ATC Class J05AR

Up to Top Level ATC Classes

Up to J - Antiinfectives for systemic use

Up to J05 - ANTIVIRALS FOR SYSTEMIC USE

Up to J05A - DIRECT ACTING ANTIVIRALS

Drugs in ATC Class: J05AR - Antivirals for treatment of HIV infections, combinations

Tradename	Generic Name
KALETRA	lopinavir; ritonavir
LOPINAVIR AND RITONAVIR	lopinavir; ritonavir

J05AR Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class J05AR (Antivirals for treatment of HIV infections, combinations) reflect a complex interplay of clinical advances, intellectual property strategies, and global health imperatives. Below is a structured analysis:

---

Market Dynamics

Growth Drivers

• Dominance of Fixed-Dose Combinations (FDCs): FDCs account for 83% of the HIV antivirals market[4], driven by their ability to simplify dosing, improve adherence, and reduce pill burden. Key examples include combinations like emtricitabine/tenofovir alafenamide/rilpivirine (J05AR19) [1] and dolutegravir-based regimens[10].
• Expanding Access: Initiatives like the Medicines Patent Pool (MPP) and partnerships with generic manufacturers have enabled broader access to FDCs in low- and middle-income countries (LMICs). For example, dolutegravir has reached 24 million people in LMICs since 2014 through voluntary licensing agreements [10].
• Market Projections: The global HIV antivirals market is projected to grow at a 4.4% CAGR, reaching USD 47 billion by 2032[4]. North America (led by the U.S.) and Europe remain dominant, while India and China are emerging as key generics hubs.

Regulatory and Clinical Trends

• Efficacy of Combination Therapies: Studies validate the effectiveness of J05AR drugs like dolutegravir/rilpivirine, which maintained 95% viral suppression rates in clinical trials [6].
• Drug Resistance Concerns: High utilization of FDCs in sub-Saharan Africa has led to rising HIV drug resistance (HIVDR) rates, necessitating continued innovation in combination therapies [9].

Challenges

• Supply Chain Vulnerabilities: Just-in-time inventory systems and demand spikes exacerbate shortages, particularly for antiretrovirals like lopinavir/ritonavir[12].
• Cost Barriers: Despite generic competition, patent thickets on combination therapies delay affordable access in LMICs [3][11].

---

Patent Landscape

Key Strategies by Originators

• Secondary Patenting: Originators extend exclusivity by patenting formulations, dosing methods, and combinations. For example:
  • Ritonavir: Over 800 patent families exist, covering polymorphs, prodrugs, and combinations. Secondary patents could extend market exclusivity until 2028[7][11].
  • Atazanavir: Novartis/Bristol-Myers Squibb filed patents on synthesis methods, formulations, and combinations (e.g., with ritonavir) to prolong protection [14].
• Combination Patents: Patents on FDCs (e.g., TDF/FTC/EFV) create barriers for generics, requiring licenses for all components. Gilead and ViiV Healthcare hold critical patents on combinations like emtricitabine/tenofovir[3][16].

Impact on Market Competition

• Patent Disputes: The European Patent Office (EPO) rejected Gilead’s patent on TDF/FTC due to lack of inventiveness, highlighting stricter scrutiny of combination claims [16].
• Generic Entry: Voluntary licensing agreements (e.g., ViiV’s partnership with MPP) and compulsory licenses (e.g., Brazil and Thailand’s actions on efavirenz) have enabled earlier generic production [3][10].

Regional Variations

• LMICs: Patent barriers persist in countries like South Africa and Ukraine, where originators maintain control over key FDCs [3][10].
• High-Income Markets: Prolonged exclusivity for combinations like dolutegravir/rilpivirine (Juluca®) limits price erosion in the EU and U.S. [6].

---

Key Takeaways

1. FDCs dominate HIV treatment, with J05AR drugs driving market growth through improved adherence and efficacy.
2. Secondary patenting and combination claims remain critical tools for originators to delay generic competition.
3. Global access initiatives like the MPP mitigate IP barriers but face challenges in regions with weak patent scrutiny.
4. Drug resistance and supply chain risks underscore the need for sustainable R&D and equitable distribution.

---

Highlight:

“The decade-long collaboration between MPP and ViiV Healthcare has been a beacon of progress in the fight against HIV, enabling 24 million people in LMICs to access innovative treatments.”

— Medicines Patent Pool, 2024 [10]

References

1. https://atcddd.fhi.no/atc_ddd_index/?code=J05AR19
2. https://atcddd.fhi.no/atc/structure_and_principles/
3. https://medicinespatentpool.org/uploads/2017/07/ARV-Snapshot_April2014Rev.pdf
4. https://www.futuremarketinsights.com/reports/hiv-antivirals-market
5. https://atcddd.fhi.no/atc_ddd_index/?code=j05ar
6. https://www.ema.europa.eu/en/medicines/human/EPAR/juluca
7. https://www.wipo.int/publications/en/details.jsp?id=230
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC7126013/
9. https://www.frontiersin.org/articles/10.3389/fitd.2021.723991/full
10. https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2024/april/mpp-10-years-anniversary/
11. https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.2012.0107
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC8299364/
13. https://pubchem.ncbi.nlm.nih.gov/compound/Lamivudine-and-raltegravir
14. https://www.wipo.int/publications/en/details.jsp?id=265
15. https://www.versitech.hku.hk/technology/a-dual-functional-antiviral-peptide-inhibits-two-entry-pathways-of-sars-cov-2
16. https://www.mondaq.com/india/patent/1407150/patent-eligibility-of-antivirals